Market News & Trends
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
Ajinomoto Bio-Pharma Services recently announce the US FDA has approved the company’s high potency vial line to manufacture a commercial product…..
DDL Implements a GMP-Compliant Quality System at its CA Lab for its CCIT Division
DDL, Inc. recently announced it has implemented a GMP-compliant quality system at its Irvine, CA, laboratory to govern its container closure integrity testing (CCIT) division.…
Quotient Sciences Supports Crinetics Pharmaceuticals With Fully Integrated Pediatric Development & Clinical Testing Program
Crinetics Pharmaceuticals and Quotient Sciences have recently announced a partnership to support Crinetics’ CRN04894 pediatric program. The partnership will utilize Quotient Sciences’ unique Translational Pharmaceutics…
PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne & San Diego
New equipment added to San Diego and Melbourne facilities will help with clinical scale and global capacity shortages….
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
Tiziana Life Sciences Ltd. recently announced it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 diabetes…..
Daré Bioscience Announces Positive Safety & Acceptability Data From Phase 1 Clinical Trial That Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy
Daré Bioscience, Inc. recently announced that Climacteric, the official journal of the International Menopause Society, published safety and acceptability results from a Phase 1 clinical…
Assembly Biosciences Announces Additional Promising Data From Phase 1a Clinical Trial; Provides Pipeline Update
Assembly Biosciences, Inc. recently provided an update of results from the final multiple-dose cohort in the ongoing Phase 1a study of its investigational next-generation, highly…
Multiple Sclerosis Market to Generate Sales of $29.8 Billion by 2030
The market for multiple sclerosis (MS) disease-modifying therapies (DMT) is set to experience moderate growth across the seven major markets (7MM*) from $18.9 billion in…
Immuneering Announces Positive Initial Phase 1 Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
Immuneering Corporation recently announced positive initial pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which was shared in…
Lisata Therapeutics & Warpnine Announce First Patient Treated in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma Trial
Lisata Therapeutics, Inc. and Warpnine Incorporated recently announced the treatment of the first patient in the iLSTA Trial of Lisata’s LSTA1 in combination with standard-of-care chemotherapy and….
Ocugen Announces Positive Preliminary Safety & Efficacy Results From Phase 1/2 Trial of Modifier Gene Therapy Product Candidate
Ocugen, Inc. recently announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the Phase 1/2 trial to assess…
Microcarrier Market is Expected to Reach $2.9 Billion
The microcarrier industry is expected to grow significantly in the near future. This is due to the increasing demand for automation and miniaturization in various…
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
atai Life Sciences recently announced the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). This Phase 1…
Ocean Biomedical Announces Notice of Allowance for Patent Application for Developing “Whole New Class” of Malaria Therapeutics
Ocean Biomedical, Inc. recently announced its Scientific Co-founder and a member of its board of directors, Jonathan Kurtis, MD, PhD, received a Notice of Allowance…
ProBioGen & ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen and ImmunOs Therapeutics recently announcd the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs’ lead program for the….
Kala Pharmaceuticals Receives FDA Fast Track Designation for Human MSC-S Therapy for Persistent Corneal Epithelial Defect
Kala Pharmaceuticals, Inc. recently announced the US FDA has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of….
Biogen Exercises Option With Denali to Develop & Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Biogen Inc. and Denali Therapeutics Inc. recently announced Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in….
Dyadic Announces Expanded Licensing Agreement to Develop & Commercialize Vaccines & Biologics for African Continent
Dyadic International, Inc. recently announced it signed an expanded licensing agreement for its C1-cell protein expression platform with South Africa’s Rubic One Health to develop,…
Blue Water Vaccines Announces Signing of Sponsored Research Agreement With The University of Texas Health Science Center at San Antonio
Blue Water Vaccines Inc. recently announced the signing of a Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to…
Meridian Medical Technologies Investing $100+ Million in Bridgeton, MO, Expansion
Meridian Medical Technologies recently announced during National Community Development Week it will expand manufacturing capabilities in….
